Search the site

BEAT-CF: Bayesian Evidence-Adaptive Tool to optimise management of Cystic Fibrosis

An innovative response-adaptive approach to driving improvements in health outcomes, applied to cystic fibrosis.

How Australian Fathers Shape the Trajectory of their Children's Wellbeing

Fathers play a critical role in children’s development, yet remain under-represented in research and associated policy outcomes, leaving critical gaps in our understanding of the role and long-term impact of father involvement.

Megan Ansell

Megan is a training specialist on the Healing Kids, Healing Families Team.

Healthy Skin and ARF Prevention

Our aim is for all kids to have healthy skin. We work with communities to reduce the burden of Strep A skin sores and sore throats to prevent rheumatic fever.

Mothers' and Fathers' Work Hours, Child Gender, and Behavior in Middle Childhood

This study examined the association between typical parental work hours (including nonemployed parents) and children's behavior in two-parent heterosexual...

ORIGIN-1 trial: study protocol for an organoid-guided N-of-1 trial evaluating CFTR modulator response in cystic fibrosis with rare non-F508del mutations

Cystic fibrosis (CF) is a genetic condition caused by mutation of the cystic fibrosis transmembrane regulator (CFTR) gene. Recently licensed modulator therapies target the defective CFTR protein and have transformed the formerly life-limiting trajectory of people with CF (pwCF).

Erdosteine in children and adults with bronchiectasis (BETTER trial): study protocol for a multicentre, double-blind, randomised controlled trial

Bronchiectasis is a worldwide chronic lung disorder where exacerbations are common. It affects people of all ages, but especially Indigenous populations in high-income nations. Despite being a major contributor to chronic lung disease, there are no licensed therapies for bronchiectasis and there remain relatively few randomised controlled trials (RCTs) conducted in children and adults.

Survival of people with cystic fibrosis in Australia

Survival statistics, estimated using data from national cystic fibrosis (CF) registries, inform the CF community and monitor disease progression. This study aimed to estimate survival among people with CF in Australia and to identify factors associated with survival.

Duration of amoxicillin-clavulanate for protracted bacterial bronchitis in children (DACS): a multi-centre, double blind, randomised controlled trial

Protracted bacterial bronchitis (PBB) is a leading cause of chronic wet cough in children. The current standard treatment in European and American guidelines is 2 weeks of antibiotics, but the optimal duration of therapy is unknown. We describe the first randomised controlled trial to assess the duration of antibiotic treatment in children with chronic wet cough and suspected PBB.

Paediatric headbox as aerosol and droplet barrier

High-flow nasal oxygen (HFNO) is frequently used in hospitals, producing droplets and aerosols that could transmit SARS-CoV-2. Our aim was to determine if a headbox could reduce droplet and aerosol transmission from patients requiring HFNO.